Tags

Type your tag names separated by a space and hit enter

Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Cancer Treat Rev. 2019 Mar; 74:49-60.CT

Abstract

Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Chang X
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, People's Republic of China; Collaborative Innovation Center of Suzhou Nano-Science and Technology, Suzhou Key Laboratory of Biomaterials and Technologies, Suzhou, People's Republic of China; Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Lu X
Nanjing Drum Tower Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Guo J
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, People's Republic of China. Electronic address: jinheguo@sina.com.
Teng GJ
Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, People's Republic of China; Collaborative Innovation Center of Suzhou Nano-Science and Technology, Suzhou Key Laboratory of Biomaterials and Technologies, Suzhou, People's Republic of China. Electronic address: gjteng@vip.sina.com.

MeSH

Ablation TechniquesAnimalsAntineoplastic Agents, ImmunologicalB7-H1 AntigenBrachytherapyCTLA-4 AntigenChemoembolization, TherapeuticHumansImmunotherapyNeoplasmsProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 Receptor

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30831375

Citation

Chang, Xiaofeng, et al. "Interventional Therapy Combined With Immune Checkpoint Inhibitors: Emerging Opportunities for Cancer Treatment in the Era of Immunotherapy." Cancer Treatment Reviews, vol. 74, 2019, pp. 49-60.
Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat Rev. 2019;74:49-60.
Chang, X., Lu, X., Guo, J., & Teng, G. J. (2019). Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 74, 49-60. https://doi.org/10.1016/j.ctrv.2018.08.006
Chang X, et al. Interventional Therapy Combined With Immune Checkpoint Inhibitors: Emerging Opportunities for Cancer Treatment in the Era of Immunotherapy. Cancer Treat Rev. 2019;74:49-60. PubMed PMID: 30831375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. AU - Chang,Xiaofeng, AU - Lu,Xiaofeng, AU - Guo,Jinhe, AU - Teng,Gao-Jun, Y1 - 2018/08/20/ PY - 2018/05/20/received PY - 2018/08/12/revised PY - 2018/08/17/accepted PY - 2019/3/5/pubmed PY - 2019/4/5/medline PY - 2019/3/5/entrez KW - Immune checkpoint inhibitor KW - Immunotherapy KW - Interventional oncology KW - Synergistic effect SP - 49 EP - 60 JF - Cancer treatment reviews JO - Cancer Treat Rev VL - 74 N2 - Immune checkpoint inhibitors-based immunotherapy offers a new effective modality in the treatment of advanced malignancies. Considering the remarkable efficacy of immune checkpoint inhibitors in clinical trials, the FDA has approved a variety of immune checkpoint inhibitors for the treatment of advanced tumors. However, only limited patients with certain cancers can benefit from monotherapy of immune checkpoint inhibitors. Interventional therapy for cancer can not only destroy the primary tumors, but also regulate the immune system through different mechanisms, which provides a potential possibility for the combination of immune checkpoint inhibitors and interventional modalities in cancer treatment. This article reviews the possible synergistic mechanisms of interventional therapy combined with immune checkpoint inhibitors and summarizes the research progress of the combined therapy in cancer treatment. SN - 1532-1967 UR - https://www.unboundmedicine.com/medline/citation/30831375/Interventional_therapy_combined_with_immune_checkpoint_inhibitors:_Emerging_opportunities_for_cancer_treatment_in_the_era_of_immunotherapy_ DB - PRIME DP - Unbound Medicine ER -